Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI WW FrankfurtCPhI WW Frankfurt
Not Confirmed
Not Confirmed
28-30 October, 2025
Not Confirmed
Not Confirmed
04-06 September, 2025
Not Confirmed
Not Confirmed
08-11 September, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI WW FrankfurtCPhI WW Frankfurt
Industry Trade Show
Not Confirmed
28-30 October, 2025
Industry Trade Show
Not Confirmed
04-06 September, 2025
Industry Trade Show
Not Confirmed
08-11 September, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/fda-approvals-drop-24-in-h1-2025-gsk-s-uti-med-vertex-s-non-opioid-painkiller-lead-pack-of-first-in-class-meds
02 Sep 2025
// PHARMAWEB
https://www.pharmiweb.com/press-release/2025-09-02/avenzo-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-avzo-103-a
08 Jul 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250708931912/en/Avenzo-Therapeutics-Announces-First-Patient-Dosed-in-Phase-12-Clinical-Study-of-AVZO-1418-a-Potential-Best-in-Class-EGFRHER3-Bispecific-Antibody-Drug-Conjugate
08 Jul 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/first-patient-dosed-in-phase-12-clinical-study-of-novel-egfrher3-bispecific-antibody-drug-conjugate-avzo-1418db-1418-302500882.html
05 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250605783144/en/Avenzo-Therapeutics-Initiates-Phase-12-Clinical-Study-of-AVZO-023-a-Potential-Best-in-Class-Novel-CDK4-Selective-Inhibitor
03 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250603522149/en/Avenzo-Therapeutics-Initiates-Phase-12-Clinical-Study-of-AVZO-1418-a-Potential-Best-in-Class-Novel-EGFRHER3-Bispecific-Antibody-Drug-Conjugate
22 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250522705047/en/Avenzo-Therapeutics-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-AVZO-1418-a-Potential-Best-in-Class-Novel-EGFRHER3-Bispecific-Antibody-Drug-Conjugate
ABOUT THIS PAGE